The QualityStocks Daily Wednesday, March 23rd, 2022

Today's Top 3 Investment Newsletters

QualityStocks(CELZ) $3.1000 +82.35%

SmallCapRelations(INND) $0.0080 +29.03%

MarketClub Analysis(LBPS) $6.0000 +28.51%

The QualityStocks Daily Stock List

Creative Medical Technology Holdings (CELZ)

QualityStocks, StockOnion, Schaeffer's, Profitable Trader Authority, PennyStockScholar, Penny Pick Finders, OTCtipReporter, HotOTC and Buzz Stocks reported earlier on Creative Medical Technology Holdings (CELZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (OTC: CELZ) is a clinical-stage biotechnology firm that is engaged in the treatment of various neurological, orthopedic, urological and immunological ailments such as stroke and erectile dysfunction, using adult stem cell treatments.

The firm is based in Phoenix, Arizona and was incorporated in 1998, on December 3. The enterprise, together with Creative Medical Health Inc. its affiliate company, is focused on regenerative medical solutions for unmet neurological and urological needs. Their team is made up of international researchers focused on regenerative medicine, whose approach to treatments makes sure that all treatments are proven to be both effective and safe.

Through partnerships with leading academic institutions and researchers, the firm has developed treatments for erectile dysfunction, established an extensive intellectual property portfolio, developed proprietary protocols and obtained Amniostem; a groundbreaking stem cell. The company is currently breaking new ground for the treatment of stroke using its amniotic-fluid based stem cell and recently launched a patient trial for erectile dysfunction at UCLA.

The firm’s product portfolio includes a treatment indicated for female infertility called OvaStem; a candidate developed for stroke patients, dubbed ImmCelz; Amniostem for the treatment of glioma, toxicity and strokes; a treatment developed for chronic lower back pain christened StemSpine; a candidate indicated for the treatment of genital dryness and loss of genital sensitivity and a treatment developed for erectile dysfunction called CaverStem.

Creative Medical Technology Holdings Inc. recently announced that the FDA issued an Investigational New Drug number to the firm’s ImmCelz candidate, which was developed to treat stroke patients. This is a major milestone for the firm and may lead to the candidate being approved for commercialization and use in the near future, which will be beneficial not only to the patients whose needs will be met but also to the company.

Creative Medical Technology Holdings (CELZ), closed Wednesday’s trading session at $3.1, up 82.3529%, on 140,009,982 volume. The average volume for the last 3 months is 139.465M and the stock's 52-week low/high is $0.0121/$9.00.

Vascular Biogenics (VBLT)

StockMarketWatch, INO.com Market Report, MarketBeat, BUYINS.NET, StreetInsider, QualityStocks, Schaeffer's, MarketClub Analysis, TraderPower, Marketbeat.com, Market FN, Barchart, Trades Of The Day, Daily Trade Alert, Greenbackers, TradersPro, Jason Bond, StockOodles, MarketArmor.com, AllPennyStocks, Trading Concepts, The Best Newsletters, Streetwise Reports and InvestorGuide reported earlier on Vascular Biogenics (VBLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vascular Biogenics Ltd. (NASDAQ: VBLT) is a clinical biopharmaceutical firm which is engaged in discovering, developing and commercializing treatments for immune-inflammatory ailments and cancer.

The company has its headquarters in Modiin-Maccabim-Reut, Israel and was incorporated in 2000, on January 27 by Jacob George and Dror Harats. The enterprise’s product brands include Vascular Therapeutics, Vascular Biogenics, Vbl, Vascular Targeting Systems and VTS.

Prior to its name change in January 2003, the firm was known as Medicard Ltd. It operates as part of the medical and diagnostic laboratories industry.

The company’s product candidates include a gene based biologic dubbed VB-111, which was developed for solid tumor indications for recurrent glioblastoma and is currently undergoing a phase 2 clinical trial for treating colorectal cancer and recurrent glioblastoma, as well as undergoing another phase 3 clinical trial for recurrent platinum-resistant ovarian cancer. The candidate recently concluded a phase 2 clinical trial which tested its effectiveness in treating thyroid cancer. The company also develops an anti-angiogenic drug known as VB-511 for oncological indications; VB-611 for solid tumors; VB-601 for inflammatory indications; VB-411 and VB-211, which are pro-angiogenic compounds indicated for treating peripheral vascular ailments.

The enterprise announced recently that its phase 3 VB-111 study for recurrent ovarian cancer had no safety issues, with a committee recommending the trial’s continuation. The candidate may soon obtain approval from the FDA if the trial’s results are successful, which would be beneficial to both the patients that suffer from this debilitating ailment and the company.

Vascular Biogenics (VBLT), closed Wednesday’s trading session at $1.63, up 13.986%, on 149,851 volume. The average volume for the last 3 months is 149,851 and the stock's 52-week low/high is $1.10/$3.04.

Enveric Biosciences (ENVB)

MarketClub Analysis, QualityStocks, StocksEarning, Schaeffer's, INO Market Report and MarketBeat reported earlier on Enveric Biosciences (ENVB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enveric Biosciences Inc. (NASDAQ: ENVB) (FRA: SLZ) is a patient-focused biotech firm specialized in enhancing the lives of patients who have suffered the adverse effects of undergoing conventional cancer treatment. The firm has a goal of testing different natural compounds, especially cannabinoids, in order to develop novel medicinal formulations that clinicians can prescribe to patients exhibiting symptoms of adverse effects of cancer treatment.

The company, which was founded in 1994 and is headquartered in Naples, Florida relies on its extensive global network of oncologists and scientists to leverage the innovative clinical developments within the cannabinoids space to identify opportunities to come up with cannabinoid-based formulations.

Enveric Biosciences has a pipeline of different products which are in varying stages of development. For example, its cannabinoid-based formulation for glioblastoma multiforme is in preclinical development, and so is its candidate for radiation dermatitis. Another candidate targeting chemotherapy-triggered peripheral neuropathy is still in the discovery phase.

At the end of 2020, David Johnson, the Chairman and CEO of the company gave the shareholders of the company an update about the performance of the firm thus far, and he gave highlights of what the company looks to achieve in the years to come, beginning with 2021. In Q1 of 2021, the company acquired an exclusive and perpetual license to five cannabinoid molecules from Diverse Biotech. These will help Enveric Biosciences access scientists and data crucial to the preclinical and clinical development of drugs that can alleviate some side effects of cancer treatment.

Additionally, the firm launched a development collaboration as well as an exclusive supply agreement with PureForm Global in the quest of the two firms to speed up the development of formulations geared at treating the pain and inflammation caused by cancer treatment.

If those development programs are successful, they will address a massive need by patients to utilize plant-based products while managing the different side effects triggered by the existing cancer therapies. Investors are bound to benefit as this demand is met by the products developed by the company.

Enveric Biosciences (ENVB), closed Wednesday’s trading session at $0.3873, up 24.3738%, on 5,810,472 volume. The average volume for the last 3 months is 5.81M and the stock's 52-week low/high is $0.243/$3.74.

Alset EHome International (AEI)

RedChip, Streetwise Reports, Wyatt Investment Research, Vantage Wire, Red Chip, QualityStocks and BUYINS.NET reported earlier on Alset EHome International (AEI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alset EHome International Inc. (NASDAQ: AEI) (FRA: 42A0) is a diversified holding firm that is focused on bio-health activities, digital transformation technology and property development in South Korea, Australia, Hong Kong, Singapore and the U.S.

The firm has its headquarters in Bethesda, Maryland and was founded in 2018 on March 7th by Heng Fai Chan. Prior to its name change in February 2021, the firm was known as HF Enterprises Inc. It serves consumers across the globe and was a former subsidiary of Hancock Fabrics Inc.

The enterprise operates through the other, bio-health, digital transformation and property development segments. The property segment takes part in 3rd party development projects while the digital technology segment is involved in mobile app product development and the provision of IT services to service providers, end-users and other commercial users. On the other hand, the other segment is involved in the provision of corporate restructuring, asset management, business development and corporate strategy services, and the bio-health segment helps finance research and sell products that promote healthy lifestyles.

The company, which is involved in sales and rental as well as home building, also designs apps for e-commerce software and enterprise messaging platforms. This is in addition to being involved in the study of nutritional chemistry to develop natural sugar alternatives, supplements and natural foods and also treat immune-related and neurological ailments.

The firm recently entered into a joint venture agreement with Novum Alpha Pte Ltd, to launch new investor-friendly cryptocurrency ETPs to the market. This move will not only generate significant value to Alset’s shareholders but also deepen its position in the digital assets space, which will be good for its growth.

Alset EHome International (AEI), closed Wednesday’s trading session at $0.6605, up 22.4963%, on 47,616,756 volume. The average volume for the last 3 months is 46.92M and the stock's 52-week low/high is $0.25/$13.73.

Bellerophon Therapeutics (BLPH)

MarketClub Analysis, MarketBeat, StockMarketWatch, QualityStocks, BUYINS.NET, StreetInsider, Stock News Now, Investing Futures, Promotion Stock Secrets, TraderPower, Money Morning, Wall Street Resources, Barchart, Schaeffer's, Marketbeat.com, StockHideout, Jason Bond and Street Insider reported earlier on Bellerophon Therapeutics (BLPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bellerophon Therapeutics Inc. (NASDAQ: BLPH) (FRA: 6L7A) is a clinical-stage therapeutics firm that is engaged in the development of products for treating cardiopulmonary ailments in the U.S.

The firm has its headquarters in Warren, New Jersey and was incorporated in 2009. Prior to its name change in January 2014, the firm was known as Ikaria Development LLC. It operates as part of the pharmaceutical manufacturing industry, under the health care sector, in the medical equipment and devices sub-industry and serves consumers in the state of New Jersey.

The company develops products using its INOpulse platform, which is part of the technology utilized in hospital to deliver inhaled nitric oxide in a continuous flow. Its products are aimed at addressing unmet medical needs in the treatment of various kinds of pulmonary hypertension.

The enterprise’s products include a pulsatile nitric oxide delivery device dubbed INOpulse indicated for pulmonary hypertension treatment that is linked to fibrotic interstitial lung disease. The product is in its phase two dose escalation stage for pulmonary hypertension linked to sarcoidosis, as well as the coronavirus, pulmonary hypertension linked to pulmonary edema from high altitude sickness and chronic thromboembolic pulmonary hypertension. In addition to this, it recently concluded a phase 2a clinical trial for pulmonary hypertension linked to chronic obstructive pulmonary disease.

The company is making significant progress in advancing its INOpulse therapy for various indications. The success of this candidate will help address unmet clinical needs for patients with different kinds of pulmonary hypertension while also extending its consumer reach, which will attract more investments into the company.

Bellerophon Therapeutics (BLPH), closed Wednesday’s trading session at $2.43, up 15.7143%, on 227,304 volume. The average volume for the last 3 months is 227,304 and the stock's 52-week low/high is $1.77/$6.33.

PhaseBio Pharmaceuticals (PHAS)

StockMarketWatch, MarketClub Analysis, Kiplinger Today, BUYINS.NET, StreetInsider, Schaeffer's, QualityStocks, MarketBeat, InvestorsUnderground, TradersPro and PoliticsAndMyPortfolio reported earlier on PhaseBio Pharmaceuticals (PHAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) (FRA: 2K4) is a clinical-stage biopharmaceutical firm that is engaged in developing and commercializing new therapies for cardiopulmonary ailments.

The firm has its headquarters in Malvern, Pennsylvania and was incorporated in 2002, on January 10th by Clay Bernardin Thorp and Ashutosh Chilkoti. It serves consumers in the United States.

The company is committed to developing new and improved drugs. It uses its recombinant biopolymers to enhance the activity, bioavailability, stability and ease of administration of peptides and proteins. Its aim is to achieve better patient compliance, fewer side effects and higher potency. The company is party to a co-development agreement with SFJ Pharmaceuticals X Ltd, which entails the development of a reversal agent known as PB2452, for an anti-platelet therapy dubbed ticagrelor.

The enterprise’s product pipeline comprises of a formulation known as PB6440, which has been developed to treat resistant hypertension; and a vasoactive intestinal peptide dubbed PB1046, which is in phase 2b clinical trials evaluating its effectiveness in treating pulmonary arterial hypertension. In addition to this, the enterprise develops a reversal agent for the anti-platelet therapy ticagrelor, known as PB25452 (bentracimab). This formulation is in phase 3 clinical trials testing its efficacy in treating patients with life-threatening bleeding events or those that require emergency surgeries.

The company is focused on advancing its bentracimab formulation, which may soon be approved for commercialization for patients in dire need of an antiplatelet reversal agent. The formulation’s success will have a positive impact on investments into the company as well as its growth.

PhaseBio Pharmaceuticals (PHAS), closed Wednesday’s trading session at $1.41, up 17.5%, on 470,778 volume. The average volume for the last 3 months is 470,247 and the stock's 52-week low/high is $0.9632/$4.24.

Energy Services of America Corp. (ESOA)

QualityStocks, MarketBeat, StocksEarning, Real Pennies and Marketbeat.com reported earlier on Energy Services of America Corp. (ESOA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Energy Services of America Corp. provides contracting services for energy related companies. The Company chiefly serves the gas, petroleum, power, chemical, and automotive industries. It also does some other incidental work including water and sewer projects. Energy Services of America is the parent company of C.J. Hughes Construction Company and Nitro Electric Company. Energy Services of America is based in Huntington, West Virginia and the Company lists on the OTCQB.

C.J. Hughes Construction Co, Inc. was established 70 years ago in West Virginia. C. J. Hughes Construction is one of the region’s foremost underground pipeline, utility, and facility construction contractors. C.J. Hughes provides an array of specialized services to the natural gas, petroleum, and water/wastewater industries.

Nitro Construction Services is a “full service” electrical contractor. Nitro provides high voltage, general power/control and instrumentation services. Since 2004, it has grown its Mechanical Services to include pipe fabrication, pipe erection, HVAC/R, as well as millwright services.

Energy Services of America builds, but does not own, natural gas pipelines for its customers. These pipelines are part of interstate and intrastate pipeline systems, which move natural gas from producing areas to consumption areas. Additionally, the Company builds and replaces gas line services to individual customers of the different utility companies. Most of its customers are in West Virginia, Virginia, Ohio, Pennsylvania, and Kentucky.

Concerning the gas industry, Energy Services of America primarily engages in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It engages in the construction of interstate and intrastate pipelines, with a focus on intrastate pipelines.

Energy Services of America provides a variety of services to the oil industry relating to pipeline, storage facilities, and plant work. For the power, chemical, and automotive industries, it provides a whole range of electrical and mechanical installations and repairs. These include substation and switchyard services, site preparation, equipment setting, pipe fabrication and installation, packaged buildings, transformers, and other ancillary work pertaining to these.

The Company’s other services include liquid pipeline construction, pump station construction, production facility construction, and water and sewer pipeline installations. Moreover, other services include different maintenance and repair services and other services related to pipeline construction.

Energy Services of America Corp. (ESOA), closed Wednesday’s trading session at $3.3, up 13.7931%, on 1,867,442 volume. The average volume for the last 3 months is 1.867M and the stock's 52-week low/high is $1.32/$3.65.

Zhihu Inc. (ZH)

MarketBeat, Schaeffer's and MarketClub Analysis reported earlier on Zhihu Inc. (ZH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zhihu Inc. (NYSE: ZH) is a company which operates an online content community platform which allows users to acquire information on various topics by asking questions which provoke views and opinions from other users.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2011. It operates as part of the internet content and information industry, under the communication services sector. The firm primarily serves consumers in China.

The company’s objective is to connect individuals and the first-hand information, expertise, know-how and knowledge held in every person’s mind. It generates its revenues from various avenues, including content-commerce solutions, paid membership service fees and advertising service fees, among others. The company primarily conducts business within the domestic market in China.

The enterprise’s content comprises of PUGC (professionally user generated content) and UGC (user generated content), which includes insights, experiences and knowledge. Individuals can make decisions, find solutions and seek inspiration, while also having fun through the content community. It provides membership services, business support services and advertising services as well as internet services, information and marketing services, technology and consulting services through its software and platform.

The company recently reported its latest financial results which show growth in its total revenues and monthly active users. It remains focused on unlocking the value of its content-centric ecosystem, enhancing its operating efficiency and ensuring sustainable long-term growth, which will not only boost revenues into the company but also encourage more investments as well.

Zhihu Inc. (ZH), closed Wednesday’s trading session at $2.89, up 2.1201%, on 11,721,526 volume. The average volume for the last 3 months is 11.619M and the stock's 52-week low/high is $1.39/$13.8492.

TROOPS Inc. (TROO)

We reported earlier on TROOPS Inc. (TROO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TROOPS Inc. (NASDAQ: TROO) (FRA: SG5) is a holding firm that is focused on the development of applications and equipment, energy saving technologies, environmental protection and the money lending business.

The firm has its headquarters in Tsuen Wan, Hong Kong and was incorporated in 2007, on July 18th. Prior to its name change in November 2021, the firm was known as SGOCO Group Ltd. The firm serves consumers around the world, with a focus on Australia and Hong Kong.

The company operates through the Corporate, Financial Technology Solutions and Services, Property Lease and Management, Money Lending Services, VR Products and Services, Green Energy Products and Services and LCD (Liquid crystal display) /LED (Light emitting diode) Product segments.

The enterprise’s products include television sets, LED/LCD monitors and other application specific products. It also provides corporate, personal and mortgage loans to high quality target borrowers. This is in addition to developing, operating and managing an online financial marketplace which connects users and financial institutions via its mobile app that offers financial technology solutions. The enterprise also provides application development, API consulting, support and maintenance, project-based consulting and software-as-a-service services. Furthermore, it offers property management and leasing services and invests in real properties to generate additional income.

The firm is focused on realizing its objective of operating as a conglomerate to strengthen synergy in its sustainable ecosystem, which will not only create value for its shareholders and bring in more investors into the firm, but also bolster its overall growth.

TROOPS Inc. (TROO), closed Wednesday’s trading session at $4.08, up 0.740741%, on 64,955 volume. The average volume for the last 3 months is 64,880 and the stock's 52-week low/high is $1.55/$29.00.

The Lion Electric (LEV)

MarketBeat and Schaeffer's reported earlier on The Lion Electric (LEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Lion Electric Co. (NYSE: LEV) (TSE: LEV) (FRA: 70U) is a zero-emission vehicle manufacturer that is engaged in the manufacture of all-electric heavy-duty and medium-duty urban vehicles.

The firm has its headquarters in Saint Jerome, Canada. It operates as part of the farm and heavy construction machinery industry, under the industrials sector. The firm serves consumers around the globe, with a focus on North America.

The company is focused on the transition to the use of all-electric vehicles, which it believes will bring about major improvements in the environment, as well as the society and overall quality of life.

The enterprise designs and manufactures class V to class VIII vehicles, which include all-electric buses, midi/minibuses and commercial urban trucks for the mass transit, paratransit and school segments. Its products include the LionM shuttle bus; the LionA and LionC school bus; and the Lion8 Refuse trucks. All of the enterprise’s vehicles are V2G enabled (vehicle-to-grid) and equipped with its telematics platform, which offers charging infrastructure agnostic and full monitoring of vehicle data. Its telematics platform also collects data like energy usage history, average energy usage, odometer readings, speed, real-time GPS tracking, greenhouse gas emissions savings and other tracking and maintenance statistics. The enterprise builds and assembles all the components of its vehicles, including bus bodies, truck cabins, battery packs and chassis.

The company recently entered into a number of partnerships with major players in the industry, i.e. CM Truck Beds, Knapheide, Thermo King and Morgan Truck Body. These partnerships will bring in additional revenue into the company while helping extend its consumer reach, which will bolster its growth.

The Lion Electric (LEV), closed Wednesday’s trading session at $8.65, off by 1.7045%, on 575,435 volume. The average volume for the last 3 months is 574,965 and the stock's 52-week low/high is $6.77/$23.45.

Gold and GemStone Mining (GGSM)

Growing Stocks Reports, QualityStocks, PickPennyStocks, PennyStockScholar, Canadian Microcap Report, Information Solutions Group, SmallCapInvestorDaily, Research Driven Investor, OTCtipReporter, Bold Stocks, David Cohen, InvestorSoup, Jet-Life Penny Stocks, Michael Stone, MicroStockProfit, Pennybuster, Beacon Equity Research, PennyStocks24, TooNiceStocks, PennyTrader, Pumps and Dumps, Stock Preacher, Stockdigest Report, StockGuru, StockTips, TheMicrocapNews and PennystockBullreport reported earlier on Gold and GemStone Mining (GGSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gold and GemStone Mining Inc. (OTC: GGSM) is a mining firm that’s focused on acquiring, exploring for and developing silver and gold properties in South and North America.

The firm has its headquarters in Irving, Texas and was incorporated in 2008, on March 5th. Prior to its name change in April 2012, the firm was known as Global GSM Solutions Inc. It operates as part of the other precious metals and mining industry, under the basic materials sector. The firm serves consumers around the globe, with a focus on the Americas.

The company is focused on forming joint ventures and strategic alliances with diamond mining and gold mining firms for the acquisition of new mining equipment, concessions and capital. It is party to a collaboration agreement with Ridgeback Mining Ltd, which involves a joint venture on a trio of gold and diamond properties located in Sierra Leone. The company’s objective is to provide maximum return for shareholders while also ensuring that local economies benefit from its activities, through the establishment of a long-lasting mutually beneficial relationship.

The enterprise’s mining claims include Sinaloa, Mexico and British Columbia, Canada, for rare earth metals and gold. The enterprise also holds 100% interest in the Gringo Viejo and Chihuahua projects, both of which are located in Mexico. The Gringo Viejo project is comprised of about 3,200 hectares.

The firm is focused on achieving its growth objectives and successfully ramping up its production, which will drive its revenues and encourage more investments, while helping create shareholder value.

Gold and GemStone Mining (GGSM), closed Wednesday’s trading session at $0.0027, up 3.8462%, on 3,974,602 volume. The average volume for the last 3 months is 3.975M and the stock's 52-week low/high is $0.0005/$0.0068.

Sorrento Therapeutics (SRNE)

MarketClub Analysis, InvestorPlace, RedChip, Schaeffer's, MarketBeat, StockMarketWatch, StreetInsider, BUYINS.NET, The Street, TradersPro, Streetwise Reports, QualityStocks, StocksEarning, Weekly Wizards, INO.com Market Report, Penny Stock 101, The Online Investor, Kiplinger Today, TraderPower, Wall Street Resources, PennyStockLocks, StockRockandRoll, Profitable Trader Authority, INO Market Report, InvestorsUnderground, HotOTC, OTCtipReporter, Buzz Stocks, Penny Pick Finders, PennyStockScholar, StockOnion, PennyStockProphet, WealthMakers, Wall Street Window, Hit and Run Candle Sticks, Barchart, VectorVest, Trades Of The Day, Daily Trade Alert, TopPennyStockMovers, StockOodles, Investors Alley, SmallCap Network, Wealth Insider Alert and Street Insider reported earlier on Sorrento Therapeutics (SRNE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sorrento Therapeutics Inc. (NASDAQ: SRNE) (LON: 0L85) (FRA: 8STN) is a clinical-stage biopharmaceutical firm that is focused on the development of therapies for neurodegenerative, viral, inflammatory and autoimmune ailments as well as cancer.

The firm has its headquarters in San Diego, California and was incorporated in 1989 by Henry H. Ji. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has thirty companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company operates through the Scilex and Sorrento Therapeutics segments. It is party to collaboration agreements with Mayo Clinic for a trial involving the use of its lymphatic drug delivery technology to deliver Ipilimumab in melanoma patients; Mount Sinai Health System for the development of an antibody therapy which targets the SARS-CoV-2 infection; Celularity Inc. and SmartPharm Therapeutics Inc., for the development of a gene-encoded antibody vaccine for the coronavirus.

The enterprise’s product pipeline comprises of its anti-CD38 therapy, which has been developed to treat multiple myeloma, as well as graft versus host disease and amyloidosis. It also develops a lidocaine delivery system dubbed ZTlido, to treat post herpetic neuralgia; a drug delivery technology dubbed Sofusa, which delivers biologics directly into an individual’s lymphatic system; and a delayed-release naltrexone hydrochloride formulation known as SP-104, for the treatment of fibromyalgia.

The firm is focused on developing and commercializing a next generation mRNA coronavirus vaccine through its Sorrento Therapeutics Mexico subsidiary. The approval of this vaccine will not only benefit the billions across the globe who are susceptible to coronavirus infections but also allow the firm to expand into various markets while bringing in additional revenue.

Sorrento Therapeutics (SRNE), closed Wednesday’s trading session at $2.45, off by 3.5433%, on 6,291,094 volume. The average volume for the last 3 months is 6.225M and the stock's 52-week low/high is $1.96/$11.07.

The QualityStocks Company Corner

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that it signed another contract with an existing hospital client. The announcement reads, “Cross-selling is the practice of selling an additional product or service to an existing client. It is one of the primary methods of generating new revenue and is, perhaps, one of the easiest ways to grow a business since there is already an established a relationship with the client and familiarity with their needs and objectives. This new contract will utilize a K5 Autonomous Security Robot to patrol the parking lots of a 206-bed medical center that serves as a care facility for nearly 3 million healthcare members throughout Northern California. If Knightscope continues to perform well, the client has identified six additional cross-selling opportunities.” To view the full press release, visit https://ibn.fm/s9LgW

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Wednesday’s trading session at $6, up 5.2632%, on 1,296,136 volume. The average volume for the last 3 months is 1.284M and the stock's 52-week low/high is $5.01/$27.50.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) recently secured new capital following the closing of a private placement with Nurture Healthy Food LLP in which the company raised more than $5 million. A recent article quotes Eat Well CEO and Director Marc Aneed as saying, “The team at Nurture are like-minded to us. They are ESG (Environmental, Social and Governance factor)-driven, they are business builders and they are all about our mission, which is to feed families globally… This gives us strategic growth internationally through commercial, retail and distribution opportunities, as well as looking at deeper parts of their agribusiness portfolio and their plant-based solutions that we can bring to the world.” Eat Well Investment Group has customers in more than 35 countries already, but, according to Aneed, the agreement with Nurture Healthy Food will help the company’s customer and distribution relationships “exponentially move into the future.” Aneed further noted, “We couldn’t be more excited to find ways to blueprint our distribution growth throughout South America, Latina America with the strength that they (Nurture Healthy Food) have today in retail.” To view the full article, visit https://ibn.fm/x8Yjd

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Wednesday’s trading session at $0.3265, up 3.3228%, on 25,465 volume. The average volume for the last 3 months is 11,965 and the stock's 52-week low/high is $0.308/$1.00.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Medical cannabis use among veterans has been a hot topic since states first started legalizing marijuana for medical use. While drug-reform proponents believe the plant has the potential to help veterans deal with chronic pain and mood disorders such as anxiety and post-traumatic stress disorder, others say it is federally prohibited for good reasons, with one being that it is a gateway drug with no medical application. This is despite research debunking this reason on numerous occasions. The latter opinion seems to be shared by the U.S. Department of Veteran Affairs (VA), the government body in charge of administrating benefit programs for military veterans and their families. The agency, which prohibits veterans from using medical marijuana at all VA centers, has released a statement noting that it will not support medical marijuana treatments for veterans as part of a new suicide-prevention grants program, which will offer eligible veterans suicide-prevention services. Still, veteran service organizations continue to advocate for more research into cannabis on the grounds that military veterans stand to benefit from these alternative treatments manufactured from the cannabis plant by state-legal entities such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF).

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Wednesday’s trading session at $0.2997, up 1.387%, on 47,290 volume. The average volume for the last 3 months is 47,290 and the stock's 52-week low/high is $0.25/$1.27.

Recent News

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company and its subsidiary, Applied Magix Inc., were spotlighted in a recent report published by the Emerging Markets. The report noted that SPYR offers a real product line that people can use to improve their lives by leveraging enhanced connectivity to their electronics. The report noted that SPYR’s wholly owned subsidiary, Applied Magix, operates in the IoT market, and develops and resells Apple(R) ecosystem-compatible products. The line of products is focused on the smart-home market. Nothing SPYR’s “proactive” decision to create an independent advisory board, the Emerging Markets article states that when young companies start advisory boards, it can open a window into the company’s future potential, add to the talent pool and signal company credibility. Noting that advisory board members were industry veterans with existing relationships that are now available to SPYR and Applied Magix. “The board member is attaching their name and reputation to the company, which will potentially enhance its profile and provide a valuable addition to its business,” the Emerging Markets announcement states. “Already, SPYR and Applied Magix have added Fred Tio, former senior creative director of Worldwide Marcom, Apple Inc., to the Applied Magix advisory board as well as Michael Teitelbaum, senior brand integrity manager at Jazwares. Again, these are industry veterans with their own Rolodexes and relationships, with time-earned experience that is now available to SPYR and Applied Magix. And more than anything, in a world of choices, these technology pros have chosen to join the SPYR and Applied Magix team.” To view the full press release, visit https://ibn.fm/Y6ke0

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Wednesday’s trading session at $0.0391, up 17.2414%, on 2,499,117 volume. The average volume for the last 3 months is 1.506M and the stock's 52-week low/high is $0.02355/$0.2075.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Last month, the French government issued a decree that allowed the growing of medical marijuana and development of the industry. The enactment took effect on March 1, 2022; however, it awaits implementation by regulators. The act features conditions and procedures for the growth and production of medical cannabis. It has also amended some clauses in the Code of Public Health to permit cultivation, production, processing, transport, possession, import and export of cannabis and its components under medical mandate. As countries around the world, including France, begin to enact cannabis reforms, there is hope that major powers such as the United States could also change their prohibitionist stance eventually so that licensed companies, including Cannabis Strategic Ventures Inc. (OTC: NUGS), can operate freely at a national level rather than having to navigate a patchwork of state laws.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Wednesday’s trading session at $0.018, up 0.558659%, on 1,279,590 volume. The average volume for the last 3 months is 1.28M and the stock's 52-week low/high is $0.014794/$0.1448.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

  • 37.5 million Americans report some degree of hearing impairment each year, many of which can’t afford the high out-of-pocket costs of prescription hearing aids
  • InnerScope offers a comprehensive portfolio of affordable products that do not require a doctor’s prescription
  • In recent months, InnerScope has made accretive acquisitions and more than tripled its staff, further cementing its position in the market as Walmart’s biggest provider of hearing aids

There is a case to be made that direct-to-consumer (“DTC”) is the future of hearing aids. Unfortunately, prescription hearing aids are rarely covered by insurance and can cost thousands of dollars. Akin to “cheaters” as a less expensive alternative to prescription reading glasses, personal sound amplification products (“PSAPs”) are available over the counter, but they aren’t as high quality or customizable as prescription hearing aids. Thanks to advancements in technology, companies like InnerScope Hearing Technologies (OTC: INND) are spearheading next-generation products that make hearing aids affordably available without a person having to set foot into a professional’s office.

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Wednesday’s trading session at $0.008, up 29.0323%, on 91,948,313 volume. The average volume for the last 3 months is 91.948M and the stock's 52-week low/high is $0.0043/$0.0599.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

  • EverGen Infrastructure Corp. is a Canadian Renewable Natural Gas (“RNG”) operator creating a world class RNG infrastructure platform
  • Renewable natural gas, which is largely obtained as a by-product of decomposing organic waste, has been hailed as a key tool in the global drive towards decarbonization
  • EverGen currently operates three organic waste processing and RNG projects in British Columbia, Canada, including Fraser Valley Biogas, Western Canada’s first RNG facility which has been in continuous operation since 2011
  • The company anticipates the sector to expand to an annual value of upwards of C$16 billion by 2030

North American Natural Gas prices have risen by over 35% in what may be the most tumultuous start to a year in recent history. Strong demand from across the North American region, coupled with multiple cold fronts, and geo-implications resulting from the Russia-Ukraine war have all come together to drive natural gas prices to some of their highest levels in recent history. Meanwhile, the combination of skyrocketing fossil fuel prices coupled with a global drive to reduce carbon emissions has prioritized the need to seek out alternative energy sources. EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British Columbia-based RNG developer, owner and operator, has been one of the principal companies involved in the development of Canada’s RNG Infrastructure, a programme seeking to combat climate change and help communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas, waste-to-energy and related infrastructure projects.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Wednesday’s trading session at $3.12, even for the day, on  volume. The average volume for the last 3 months is 300 and the stock's 52-week low/high is $2.78/$4.21.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

The Biden administration recently imposed a ban on imports from Russia following the Eastern European country’s invasion of Ukraine. Uranium, which is a key radioactive metal used to make fuel for nuclear reactors in the United States, wasn’t included in this ban. However, the U.S. is considering imposing sanctions on Rosatom State Nuclear Energy Corp, a Russian state atomic corporation, which caused the price of uranium to rise to $60. America’s dependence on foreign sources for uranium leaves its nuclear energy sector vulnerable to conflict. Currently, Russia exports 20% of the uranium used in reactors in the United States. The country is also the major supplier of uranium that’s fuel-ready to the global market. Experts believe that imposing sanctions on imports from Russia will increase the cost of uranium for nuclear power plants around the globe, which will leave American utilities open to more fluctuations. But uranium miners in America see this as an opportunity to make bank by restarting idle uranium mines while helping the country fight back against Russia. For instance, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), the company that owns the only uranium mill in the U.S., is considering restarting up some of its mines. The CEO of this major uranium mining firm, Mark Chalmers, stated that the U.S. had the ability to be more self-sufficient, revealing that if the price of uranium rose or stayed the same, the firm would bring some of its operations back online.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday’s trading session at $9.91, off by 2.6523%, on 5,034,246 volume. The average volume for the last 3 months is 4.989M and the stock's 52-week low/high is $4.32/$11.39.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that its recently acquired JustCBD brand is planning to open four brick-and-mortar locations in 2022 in the Czech Republic and Germany, with an additional 50 store openings planned in 2023. The company is partnering with German-based Greenyard to manage the new retail locations, which are under construction with planned openings in Q2 2022. Flora Growth anticipates additional growth throughout Europe moving forward. According to the announcement, the new stores will offer JustCBD’s complete product line, including gummies, tinctures, vape cartridges, creams, pet wellness, and more. FLGC also plans to distribute JustCBD products throughout Germany, the Czech Republic, Poland, Austria, Switzerland, Ukraine, Georgia and Estonia through different distribution methods other than the new retail locations. “As a leading wellness brand in the United States, we believe the quality of JustCBD’s sought-after products will result in strong demand in the European market,” said JustCBD founder Hussein Rakine in the press release. “This inaugural European expansion is expected to be the first of many initiatives in a broader international growth strategy. We couldn’t be more excited about launching this partnership with Greenyard and are honored to bring our quality wellness products to the European market.” To view the full press release, visit https://ibn.fm/7QMOz

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday’s trading session at $1.87, off by 2.0942%, on 410,932 volume. The average volume for the last 3 months is 409,459 and the stock's 52-week low/high is $1.31/$21.45.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of automated indoor “micro-farms” called Grow Pods and related equipment and supplies, today announced that it has selected the corporate communications expertise of IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outletsvarious newsletterssocial media channels, wire services via InvestorWire, blogs and additional outreach tools to generate greater awareness for Advanced Container Technologies. “The USDA has stated that vertical farming practices utilizing indoor micro-farms are no longer ‘futuristic’ concepts, and Advanced Container Technologies is capitalizing on this growing opportunity through its distribution of Grow Pods,” said IBN Director of Client Solutions Chris Johnson. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it explores a possible acquisition of GP Solutions and continues to refine and commercialize its line of Medtainer containers.” To view the full press release, visit https://ibn.fm/WSFJS

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday’s trading session at $0.9999, off by 0.01%, on 476 volume. The average volume for the last 3 months is 476 and the stock's 52-week low/high is $0.66/$5.00.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Activists in Colorado have decided to proceed with a single proposal to legalize psilocybin. This proposal, which is one of the quartet of psychedelic reform ballot measures drafted and filed for this year’s ballot, will also offer a pathway for the sealing of prior conviction records and establish healing centers where individuals can use psilocybin for therapeutic purposes. The measure, known as Initiative 58, would also allow regulators to decide whether to legalize mescaline, ibogaine and DMT. Veronica Perez and Kevin Matthews, who managed the campaign behind Denver’s historic vote to locally decriminalize psilocybin in 2019, are the brains behind this measure. In an interview, Matthews explained that Initiative 58 was chosen because it was a comprehensive policy that would ensure that all the residents of Colorado have the option to access these natural medicines. He added that supporters were excited to start gathering signatures from voters, which would allow the proposal to appear on the coming ballot. As these winds of change in favor of psychedelics blow across the nation, biopharm companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are also doing whatever they can to bring to market psychedelic-based pharmaceutical formulations that are approved by the FDA and other regulators around the world. The American Hospital Association (AHA) is urging the Senate Finance Committee to strengthen financial support programs that assist healthcare systems to address the shortage of providers of behavioral healthcare. The organization recently penned a statement to Congress highlighting how the coronavirus pandemic increased the demand for care and aggravated the behavioral health crisis. All individuals, but particularly children and adolescents, are experiencing high rates of depression, anxiety and substance use disorder, among other mental issues. However, barriers hinder them from acquiring proper care. Currently, health systems and hospitals are finding it hard to offer sufficient behavioral healthcare services to youths because of provider and psychiatric bed shortages.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday’s trading session at $0.77, off by 4.9265%, on 1,030,265 volume. The average volume for the last 3 months is 1.024M and the stock's 52-week low/high is $0.736/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtual Growth Conference. The event, presented by Maxim Group LLC and hosted by M-Vest, is slated to take place March 28-30, 2022. In addition to the company's corporate presentation available on demand for registered attendees, Climaco will participate in a live fireside chat moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group, at 2:30 p.m. ET on Wednesday, March 30. The conference will be live on M-Vest. Interested parties should visit https://ibn.fm/Rp9V3 to sign up to become an M-Vest member, reserve a seat and attend the conference. To view the full press release, visit https://ibn.fm/iiF9Q

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday’s trading session at $0.3321, off by 2.3235%, on 528,465 volume. The average volume for the last 3 months is 511,896 and the stock's 52-week low/high is $0.2453/$2.76.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.